BeiGene Starts Global Phase III Trial Of BTK Inhibitor

December 27, 2017 -- BeiGene has started a global Phase III trial of its lead molecule, BGB-3111, a Bruton's tyrosine kinase (BTK) inhibitor. The candidate will be administered to patients with Waldenström’s macroglobulinemia. WM is a rare disease, though ultimately BeiGene will seek approval of BGB-3111 for other forms of lymphoma. In the trial, BeiGene's candidate will be compared to Imbruvica, an already approved drug. BeiGene believes BGB-3111 will prove to have a better side effect profile than Imbruvica because it is more selective. In earlier trials, BGB-3111 demonstrated an overall response rate of 94%, including a major response rate of 78%, at a median follow-up time of 9.6 months.

Back to news